Form 13-F position report

GRITSTONE BIO INC COM (DE)

Reported by STATE STREET CORPORATION

GRTS CUSIP 39868T105 Manager CIK 0000093751

Reported 0 shares, down 312,030 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q4 2024
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 25 Through Q4 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 47245000
2022-03-31 3996000
2022-06-30 624000
2022-09-30 523000
2022-12-31 967139
2023-03-31 759857
2023-06-30 2949057
2023-09-30 2746181
2023-12-31 3633246
2024-03-31 4626707
2024-06-30 203802
2024-09-30 180946
2024-12-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

13 quarters
Quarterly reported position history for GRITSTONE BIO INC COM (DE) held by STATE STREET CORPORATION.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2024 Reduced 0 -312,030 (-100.0%) 0 $0 2025-02-14
Q3 2024 Reduced 312,030 -17,800 (-5.4%) < 0.01% $180,946 2024-11-14
Q2 2024 Reduced 329,830 -1,470,445 (-81.7%) < 0.01% $203,802 2024-08-14
Q1 2024 Added 1,800,275 +19,272 (1.1%) < 0.01% $4,626,707 2024-05-15
Q4 2023 Added 1,781,003 +184,386 (11.5%) < 0.01% $3,633,246 2024-02-14
Q3 2023 Added 1,596,617 +84,280 (5.6%) < 0.01% $2,746,181 2023-11-14
Q2 2023 Added 1,512,337 +1,239,007 (453.3%) < 0.01% $2,949,057 2023-08-14
Q1 2023 Reduced 273,330 -7,000 (-2.5%) < 0.01% $759,857 2023-05-15
Q4 2022 Added 280,330 +76,800 (37.7%) < 0.01% $967,139 2023-02-14
Q3 2022 Reduced 203,530 -54,300 (-21.1%) < 0.01% $523,000 2022-11-15
Q2 2022 Reduced 257,830 -712,152 (-73.4%) < 0.01% $624,000 2022-08-15
Q1 2022 Reduced 969,982 -2,703,797 (-73.6%) < 0.01% $3,996,000 2022-05-16
Q4 2021 Added 3,673,779 +2,912,305 (382.5%) < 0.01% $47,245,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

56 managers reported GRITSTONE BIO INC COM (DE) for Q4 2024.

Managers reporting GRITSTONE BIO INC COM (DE) in Q4 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Baader Bank Aktiengesellschaft New 67,142 +67,142 < 0.01% $751 1 qtr
EverSource Wealth Advisors LLC Unchanged 1,724 0 < 0.01% $22 6 qtrs
Siren L L C Reduced 0 -3,318,093 0 $0 2 qtrs
Redmile Group LLC Reduced 0 -4,920,178 0 $0 26 qtrs
UBS Group AG Reduced 0 -681 0 $0 25 qtrs
VANGUARD GROUP INC Reduced 0 -4,643,928 0 $0 26 qtrs
BNP PARIBAS FINANCIAL MARKETS Reduced 0 -1,213 0 $0 24 qtrs
Point72 Asia Singapore Pte Ltd Reduced 0 -75,434 0 $0 3 qtrs
Forum Financial Management LP Reduced 0 -254,748 0 $0 8 qtrs
VICTORY CAPITAL MANAGEMENT INC Reduced 0 -542,380 0 $0 5 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2024
Filed
February 14, 2025
Filing type
13F-HR
Position type
COM

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.